Skip to main content

Table 3 Plasma levels of LCN2, MMP9, and MMP9/LCN2 complex in different types of nAMD patients and controls

From: Plasma level of lipocalin 2 is increased in neovascular age-related macular degeneration patients, particularly those with macular fibrosis

Variable

Control (N = 43, Mean ± SD)

CNV (N = 108, Mean ± SD)

RAP (N = 32, Mean ± SD)

PCV (N = 23, Mean ± SD)

p value

Age

73.4 ± 8.9

78.9 ± 7.8†

80.7 ± 8.7†

71.6 ± 8.9

 

LCN2 (ng/ml)

153.24 ± 49.55

186.60 ± 71.57*

176.08 ± 82.70

168.36 ± 70.68

0.108a

MMP9 (ng/ml)

124.16 ± 63.12

114.42 ± 58.93

111.18 ± 96.94

126.40 ± 65.09

0.301a

MMP9/LCN2 (ng/ml)

188.38 ± 45.12

176.51 ± 53.35

181.69 ± 66.07

196.29 ± 66.05

0.370b

  1. CNV choroidal neovascularisation, RAP retinal angiomatous proliferation, PCV polypoidal choroidal vasculopathy
  2. †P < 0.05 compared to controls
  3. *P = 0.006 compared to controls in univariate analysis
  4. aKruskal-Wallis one-way analysis of variance on log transformed data
  5. bOne-way ANOVA
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us